222 related articles for article (PubMed ID: 36496279)
1. The Impact of Naloxone Coprescribing Mandates on Opioid-Involved Overdose Deaths.
Sohn M; Delcher C; Talbert JC; Cheng Y; Xu Y; Jadhav ED; Freeman PR
Am J Prev Med; 2023 Apr; 64(4):483-491. PubMed ID: 36496279
[TBL] [Abstract][Full Text] [Related]
2. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
[TBL] [Abstract][Full Text] [Related]
3. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
[TBL] [Abstract][Full Text] [Related]
4. State Laws That Require Coprescribing Opioids and Naloxone and Codispensing Practices.
Tormohlen KN; Schmid I; Stuart EA; Davis C; McGinty EE
Am J Prev Med; 2024 Jan; 66(1):138-145. PubMed ID: 37739192
[TBL] [Abstract][Full Text] [Related]
5. Assessment of a Naloxone Coprescribing Alert for Patients at Risk of Opioid Overdose: A Quality Improvement Project.
Nelson SD; McCoy AB; Rector H; Teare AJ; Barrett TW; Sigworth EA; Chen Q; Edwards DA; Marcovitz DE; Wright A
Anesth Analg; 2022 Jul; 135(1):26-34. PubMed ID: 35343932
[TBL] [Abstract][Full Text] [Related]
6. Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.
Sohn M; Talbert JC; Huang Z; Lofwall MR; Freeman PR
JAMA Netw Open; 2019 Jun; 2(6):e196215. PubMed ID: 31225895
[TBL] [Abstract][Full Text] [Related]
7. Associations between naloxone prescribing and opioid overdose among patients with acute and chronic pain conditions.
Qeadan F; Madden EF
Addiction; 2022 Feb; 117(2):457-471. PubMed ID: 34286895
[TBL] [Abstract][Full Text] [Related]
8. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates.
Tabatabai M; Cooper RL; Wilus DM; Edgerton RD; Ramesh A; MacMaster SA; Patel PN; Singh KP
J Prim Care Community Health; 2023; 14():21501319221147246. PubMed ID: 36625264
[TBL] [Abstract][Full Text] [Related]
10. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
[TBL] [Abstract][Full Text] [Related]
11. Impact of the naloxone standing order on trends in opioid fatal overdose: an ecological analysis.
Taylor M; Pradhan A; Ogando YM; Shaya F
Am J Drug Alcohol Abuse; 2022 May; 48(3):338-346. PubMed ID: 35467459
[No Abstract] [Full Text] [Related]
12. The changing landscape of naloxone availability in the United States, 2011 - 2017.
Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
[TBL] [Abstract][Full Text] [Related]
13. Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect.
Manchikanti L; Singh VM; Staats PS; Trescot AM; Prunskis J; Knezevic NN; Soin A; Kaye AD; Atluri S; Boswell MV; Abd-Elsayed A; Hirsch JA
Pain Physician; 2022 Mar; 25(2):97-124. PubMed ID: 35322965
[TBL] [Abstract][Full Text] [Related]
14. The role of managed care pharmacy in coprescribing naloxone for patients with specific risk: recommendations from the AMCP Addiction Advisory Group.
Skelton JB; Dharbhamalla V
J Manag Care Spec Pharm; 2022 Jan; 28(1):100-106. PubMed ID: 34949114
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Centers for Disease Control (CDC) recommendations and the risk index for overdose or serious opioid-induced respiratory depression (RIOSORD) tool for guiding naloxone coprescribing.
Herndon CM; Kirby TR; Madison KJ; Kerr JL
J Opioid Manag; 2023; 19(2):111-116. PubMed ID: 37270418
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting.
Watson A; Guay K; Ribis D
Am J Health Syst Pharm; 2020 Mar; 77(7):568-573. PubMed ID: 32207821
[TBL] [Abstract][Full Text] [Related]
17. Opportunities to Prevent Overdose Deaths Involving Prescription and Illicit Opioids, 11 States, July 2016-June 2017.
Mattson CL; O'Donnell J; Kariisa M; Seth P; Scholl L; Gladden RM
MMWR Morb Mortal Wkly Rep; 2018 Aug; 67(34):945-951. PubMed ID: 30161105
[TBL] [Abstract][Full Text] [Related]
18. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
[TBL] [Abstract][Full Text] [Related]
19. Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019.
Quinn K; Kumar S; Hunter CT; O'Donnell J; Davis NL
Drug Alcohol Depend; 2022 Jun; 235():109467. PubMed ID: 35461083
[TBL] [Abstract][Full Text] [Related]
20. Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose.
Abouk R; Pacula RL; Powell D
JAMA Intern Med; 2019 Jun; 179(6):805-811. PubMed ID: 31058922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
